Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

Go back to Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
(NASDAQ: VIR) Delayed: 10.58 -0.23 (2.13%)
Previous Close $10.81    52 Week High
Open $10.57    52 Week Low
Day High $10.79    P/E N/A 
Day Low $10.45    EPS
Volume 1,855,256